Artiva Biotherapeutics

ARTVPhase 2

San Diego, United Statesartivabio.com

Artiva Biotherapeutics is pioneering accessible NK cell therapies with a mission to treat devastating autoimmune diseases and cancers. Leveraging a proprietary manufacturing platform and a strategic partnership with GC Cell Corporation, Artiva's lead program, AlloNK®, is in multiple Phase 1/2 trials for conditions like rheumatoid arthritis and Sjögren's disease. The company differentiates itself through a scalable, allogeneic approach designed to enable outpatient treatment and broad patient access.

Market Cap

$131.5M

Focus

Cell & Gene Therapy

ARTV · Stock Price

USD 5.326.68 (-55.67%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for manufacturing allogeneic natural killer (NK) cells from pre-selected umbilical cord blood, yielding non-genetically modified, cryopreserved, off-the-shelf cell therapies designed to enhance antibody-dependent cellular cytotoxicity (ADCC).

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleukin-2	Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Allogeneic NK Cells	Refractory Rheumatoid Arthritis (RA)	Phase 2
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Fludarabine + Bendamusti...	Non Hodgkin Lymphoma	Phase 1/2
AB-201 + Cyclophosphamide + Fludarabine	Breast Cancer	Phase 1/2
GCC2005 + Cyclophosphamide + Fludarabine	Lymphoma, T-Cell	Phase 1

Funding History

Total raised: $198M

Series B$120MRA Capital ManagementMay 15, 2022

Series A$78M5AM VenturesDec 15, 2020

Opportunities

Significant growth opportunity lies in demonstrating efficacy in large autoimmune disease populations with high unmet need, potentially enabling first-to-market allogeneic cell therapy approvals.

The platform's flexibility allows for combination with a wide array of monoclonal antibodies, creating a pipeline-in-a-product opportunity across both autoimmunity and oncology.

Risk Factors

Key risks include clinical trial failures, regulatory hurdles for novel cell therapies, challenges in market adoption and reimbursement for cell-based autoimmune treatments, and intense competition from both autologous cell therapies and other allogeneic platforms.

Competitive Landscape

Artiva competes with autologous CAR-T companies in autoimmunity (e.g., Kyverna, Cabaletta) and oncology (e.g., Kite, BMS), and other allogeneic cell therapy developers (e.g., Fate Therapeutics). Its differentiation is based on a non-genetically modified, scalable NK cell platform designed for outpatient use with a potentially superior safety profile.